A New Modality

Exosome therapeutics have the potential to open the door to an entirely new way to address a vast range of illnesses.

Codiak’s proprietary engEx™ technology platform for exosome engineering and manufacturing represents a transformative step in the treatment of disease, enabling the development of therapies for diseases that are currently considered intractable. Using this breakthrough platform, we can produce exosomes that have precise and intentionally chosen properties and make them at industrial quality and scale.

Broad Pipeline Potential

Using our engEx™ Platform, Codiak is developing a pipeline of product candidates that may have a transformative impact for patients with a broad spectrum of serious diseases. With an initial focus on immune cells, we are exploring the significant potential of this versatile and precise approach to engineering exosomes in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurogenerative disorders, and rare diseases.

Purity at Scale

Codiak has addressed the challenges of industrial-scale exosome production. We have developed proprietary methods to engineer, produce, and purify exosomes at the scale and quality necessary to bring exosome therapeutics to patients.